70 results
8-K
EX-99.1
AGRX
Agile Therapeutics Inc
9 Nov 23
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:15am
protection for Twirla and our product candidates, the lingering effects of the COVID-19 pandemic on our commercialization efforts, clinical trials, supply
8-K
EX-99.1
ina028cmesd
9 Aug 23
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8:10am
424B4
3xfa qi6rxba6p0u
24 May 23
Prospectus supplement with pricing info
4:05pm
8-K
EX-99.1
fg57gb
11 May 23
Agile Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:15pm
8-K
w509psn8uw5q88s2
28 Apr 23
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
4:40pm
8-K
EX-99.1
jm22ex7i
28 Apr 23
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
4:40pm
8-K
EX-99.1
vamlsxgtjpxuw3na
7 Nov 22
Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
2l4mxrp1nmrrkvah
7 Oct 22
Agile Therapeutics Announces Reorganization of Leadership Team
4:30pm
424B5
aayvkm
23 Aug 22
Prospectus supplement for primary offering
4:30pm